This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Intracerebral Haemorrhage — Acute Intensive Care, V268뇌내출혈 — 급성기 집중치료

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I61 (intracerebral haemorrhage) | Special Copayment Reduction: V268 (Special Copayment Reduction for acute intensive care of cerebrovascular disease: intensive care unit admission, 5% copayment for up to 30 days)
B. SynonymsCerebral hemorrhage (hemorrhagic stroke), non-traumatic intracerebral hemorrhage, spontaneous intracerebral hemorrhage (sICH), hemorrhagic stroke
C. Adult onsetIncidence surges after age 55; hypertension-related ICH most often occurs in people in their 50s to 80s. Incidence is higher in Asians than in Westerners.
1. HistorySummarizes the historical development of ICH treatment from Wepfer's 17th-century description to the era of INTERACT, ATACH, and ENRICH.
2. CausesHypertension (about 50–70%), cerebral amyloid angiopathy (CAA), anticoagulants, AVM, tumors, and vasculitis are the main causes.
3. GeneticsAssociations include CAA-related ApoE ε2·ε4; APOE and COL4A1 variants; and NOTCH3 (CADASIL) mutations related to cerebral small vessel disease.
4. General epidemiologyAbout 2.7 million cases worldwide annually; about 10–15% of strokes; incidence and mortality in East Asia are higher than in the West.
5. PathophysiologySmall artery rupture (lipohyalinosis·microaneurysm rupture) → hematoma formation·expansion → a cascade of injury with perihematomal edema·increased intracranial pressure.
6. SymptomsSudden headache, hemiparesis, speech disturbance, decreased consciousness; onset during activity is common, with worsening over minutes to hours.
7. SignsDecreased GCS, hemiparesis·hemisensory loss, pupillary abnormalities, Cushing triad; specific signs appear according to hematoma location.
8. ScreeningNon-contrast CT is first-line; the spot sign (CTA) for predicting hematoma expansion and MRI-SWI for CAA assessment are adjunctive tests.
9. DiagnosisAfter confirming hemorrhage on CT, cause evaluation (CTA, MRI, DSA); the ICH score classifies severity and 30-day mortality risk.
10. TreatmentRapid blood pressure lowering (target 140 mmHg), coagulation reversal (ANNEXA-I), MIPS minimally invasive surgery (ENRICH), and intensive care unit management are key.
11. Prognosis30-day mortality 35–50%; about 20% achieve functional independence at 1 year; the ICH score is useful for predicting prognosis.
12. PreventionHypertension treatment is the top priority; smoking cessation, limiting excessive alcohol intake, appropriate anticoagulant use, and fall prevention are key secondary prevention measures.
13. ReferencesGreenberg SM et al. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage (AHA/ASA) … and 9 other papers

1. History

The history of intracerebral haemorrhage (ICH) parallels the history of stroke medicine. In 1658, the 17th-century Swiss physician Johann Jacob Wepfer described in his book Apoplexia, based on autopsy findings, that rupture of cerebral vessels is a cause of stroke. Wepfer described a clinical syndrome arising when an artery ruptures within the brain parenchyma and blood invades brain tissue, which is regarded as a pioneering description of the modern concept of ICH.

In 1868, in the 19th century, Jean-Martin Charcot and Charles Bouchard discovered microaneurysms in the small cerebral arteries of hypertensive patients and proposed the Charcot-Bouchard aneurysm theory, according to which their rupture causes intracerebral hemorrhage. This is still recognized as an important pathogenic theory of hypertensive ICH. The introduction of CT (1973) brought a revolution that made rapid and noninvasive diagnosis of ICH possible. Before CT, bloody CSF was confirmed by lumbar puncture, or vascular displacement was assessed indirectly by cerebral angiography. After the introduction of CT, the location, size, and shape of ICH and the presence of accompanying intraventricular hemorrhage could be accurately determined.

In the 1990s, advances in MRI and SWI (susceptibility weighted imaging) elucidated the imaging features of cerebral amyloid angiopathy (CAA), such as CAA-related ICH, microbleeds, and cortical superficial siderosis. From the 2010s onward, the INTERACT2 (2013) and ATACH-2 (2016) studies evaluated strategies of early rapid blood pressure lowering. The 2022 AHA/ASA guideline on the management of spontaneous intracerebral hemorrhage is the most comprehensive guideline, reflecting the latest evidence such as the bundled care of INTERACT3 (JAMA 2022), minimally invasive surgery in ENRICH (NEJM 2023), and coagulation reversal with andexanet alfa in ANNEXA-I (NEJM 2023). In 2024, updated ICH performance measures were published, contributing to the standardization of care from admission through post-discharge.


2. Causes

Causes of spontaneous intracerebral hemorrhage are broadly divided into primary and secondary.

Hypertensive ICH is the most common cause, accounting for about 50–70% of all cases. Chronic hypertension causes the small arteries of the brain (small artery diameter 50–700 μm) to rupture after lipohyalinosis or formation of Charcot-Bouchard microaneurysms. Predilection sites are the putamen (about 35%), thalamus (about 20%), cerebellum (about 10%), brainstem (about 5%), and subcortical white matter (lobar, about 20%). Putaminal, thalamic, cerebellar, and brainstem hemorrhages are mostly hypertensive, whereas lobar hemorrhages are mostly due to CAA and AVM.

Cerebral amyloid angiopathy (CAA) is the most important cause of lobar hemorrhage in people aged 65 or older. Beta-amyloid protein is deposited in the walls of small cortical vessels, weakening the vessel wall and causing rupture. CAA-related ICH is characterized by lobar location, a tendency to recur, and multiple microbleeds on MRI-SWI. Anticoagulants and antiplatelet agents are emerging as an increasing cause of ICH. Warfarin-related ICH has larger hematomas and a poorer prognosis than ordinary ICH. Direct oral anticoagulant (DOAC)-related ICH is less frequent than with warfarin and tends to have smaller hematomas. Secondary causes include cerebral AVM, cavernous malformations, cerebral aneurysms, primary and metastatic brain tumors, cerebral vasculitis, moyamoya disease, venous thrombosis, and cocaine and amphetamine abuse.


3. Genetics

Genetic factors in intracerebral hemorrhage differ by cause type.

In cerebral amyloid angiopathy (CAA), the APOE (apolipoprotein E) genotype is the most important genetic risk factor. The ApoE ε4 allele promotes vascular amyloid deposition, raising the risk of CAA and recurrent hemorrhage. ApoE ε2 deposits amyloid while also weakening vessel wall integrity, increasing the risk of CAA-related hemorrhage (a paradoxical effect). The association with Alzheimer disease is also shared through ApoE ε4.

COL4A1/COL4A2 gene variants encode type IV collagen alpha chains; when these are mutated, basement membrane structure is weakened, and diffuse small vessel disease and intracerebral hemorrhage may develop. Although rare, they are clinically important and must be differentiated especially in ICH in children and young adults. CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is caused by mutations in the NOTCH3 (19p13) gene, and ICH can occur as part of cerebral small vessel disease. CARASIL (autosomal recessive cerebral small vessel disease), caused by HTRA1 gene variants, shows a similar clinical picture. In GWAS of sporadic ICH, association signals have been identified at several loci besides APOE and COL4A1/A2, but clinical genetic testing is currently performed selectively only when a hereditary syndrome is suspected.


4. General epidemiology

Spontaneous intracerebral hemorrhage is estimated to occur in about 2.7 million cases annually worldwide (Krishnamurthi et al., 2013). It accounts for about 10–15% of all strokes but about 40–50% of stroke deaths, a disproportionately large mortality burden.

By sex, it is slightly more common in men (male:female = about 1.2–1.5:1). By age, incidence rises sharply after age 55, and ICH under age 45 accounts for about 10–15% of all cases. Regionally, East Asia (China, Korea, Japan, Vietnam) shows markedly higher incidence and mortality than the West. The incidence of ICH in Korea is reported at about 30–40 per 100,000, and the proportion of ICH among all strokes is about 20–25%, higher than in the West (about 10%).

Hypertension is the strongest modifiable risk factor for ICH, and hypertension-related ICH predominates in Korea as well. The proportion of anticoagulant-related ICH is gradually increasing with growing anticoagulant use, and CAA-related ICH is also increasing with population aging. Socioeconomic inequality also affects ICH epidemiology, as low-income and less-educated groups have a higher risk of ICH due to poor hypertension control.


5. Pathophysiology

The pathophysiology of spontaneous intracerebral hemorrhage can be understood in three stages: hematoma formation, expansion, and injury to surrounding brain tissue.

Onset of bleeding and hematoma formation: In hypertensive ICH, small cerebral arteries with lipohyalinosis or Charcot-Bouchard microaneurysms rupture, and blood enters the brain parenchyma. In CAA, small cortical vessels weakened by amyloid deposition rupture. As blood infiltrates the brain parenchyma, brain tissue is separated and a hematoma forms. Blood within the hematoma clots over 30 minutes to several hours, and during this process coagulation factors such as thrombin exert local neurotoxicity.

Hematoma expansion: The hematoma expands in about 30–40% of patients within 3 hours of onset and in about 20% within 24 hours. The spot sign on CTA (contrast extravasation within the hematoma) is an important predictor of hematoma expansion. Anticoagulant use, high initial blood pressure, irregular hematoma shape, and hematoma heterogeneity are also risk factors for hematoma expansion. Hematoma expansion is strongly associated with early clinical deterioration and poor prognosis.

Perihematomal edema (PHE): Cytotoxic and vasogenic edema develop together around the hematoma. Thrombin from the coagulation cascade, hemoglobin breakdown products (heme, iron ions), complement activation, and inflammatory cytokines disrupt the blood-brain barrier and exert neurotoxicity. PHE increases gradually over 72 hours to 2 weeks and is an important cause of increased intracranial pressure and neurological deterioration. Increased intracranial pressure can lead to brain herniation and brainstem compression.


6. Symptoms

The clinical symptoms of intracerebral hemorrhage characteristically begin suddenly and worsen over minutes to hours. Unlike ischemic stroke, onset during activity is common.

Headache occurs in about 40–60% of ICH patients and is often less severe than in SAH, though it can be quite severe. Particularly severe occipital headache is characteristic of cerebellar hemorrhage. Focal neurological deficits vary with hematoma location. Putaminal hemorrhage: contralateral hemiparesis, hemisensory loss, homonymous hemianopia, aphasia (with dominant hemisphere involvement). Thalamic hemorrhage: hemisensory loss (more prominent than hemiparesis), decreased consciousness, vertical gaze impairment. Cerebellar hemorrhage: severe dizziness, vomiting, incoordination, gait disturbance (characteristically, limb weakness is mild or absent). Pontine hemorrhage: rapid decline in consciousness, quadriplegia, high fever, sweating, pinpoint pupils.

Nausea and vomiting commonly accompany ICH in association with increased intracranial pressure. Decreased consciousness appears with large hematomas or with accompanying intraventricular hemorrhage or hydrocephalus and reflects severity. Seizures occur in about 4–10% of ICH patients and are more common in lobar hemorrhage.


7. Signs

Characteristic signs appear on physical examination of patients with intracerebral hemorrhage.

Vital signs: An abrupt rise in blood pressure (a physiological response to the acute neurological condition or a reflection of preexisting hypertension) is commonly observed. The Cushing triad (hypertension, bradycardia, irregular respiration) appears when intracranial pressure is very high and is an urgent sign suggesting impending herniation. Level of consciousness: Assessed with the GCS; GCS on admission is an important prognostic factor. GCS ≤8 requires immediate airway management. Pupillary abnormalities: Ipsilateral pupillary dilation and fixation suggest uncal herniation and require emergency surgery or osmotic therapy. Pinpoint pupils in pontine hemorrhage reflect damage to the sympathetic fibers of the pons.

Location-specific signs: Thalamic hemorrhage is characterized by vertical gaze palsy (downgaze palsy, resembling Parinaud syndrome) and contralateral hemisensory loss. Cerebellar hemorrhage is characterized by ataxia, nystagmus, and falls on attempting to walk. Early deterioration in cerebellar hemorrhage requires special attention because it is due to acute hydrocephalus from compression of the cerebral aqueduct. Extensor posturing or flexor posturing in the motor response suggests a serious structural abnormality.


8. Screening

Rapid screening and assessment of severity in intracerebral hemorrhage are essential for intensive care unit admission (V268 applied) and treatment decisions.

Non-contrast brain CT is central to emergency screening. ICH appears on CT as a hyperdense lesion of acute blood, and size, location, intraventricular extension, midline shift, and accompanying hydrocephalus can be assessed quickly. CT is essential for distinguishing ischemic from hemorrhagic stroke. The spot sign on CT angiography (CTA) is a finding of contrast extravasation within the hematoma on CTA and is a strong predictor of hematoma expansion (positive predictive value about 85–90%). In spot sign-positive patients, aggressive blood pressure lowering and coagulation reversal to prevent hematoma expansion are even more important.

Basic blood tests—complete blood count, coagulation (PT-INR, aPTT, platelets), serum electrolytes, blood glucose, renal function, liver function—should be performed immediately. Confirming whether and which anticoagulant is being taken is important in determining the treatment direction. ECG and cardiac enzymes (troponin) are needed to evaluate neurogenic cardiac injury. Brain MRI is secondary to CT in acutely unstable patients but is used for CAA diagnosis (multiple microbleeds on SWI, T2*), identification of underlying lesions, and treatment planning.


9. Diagnosis

After ICH is confirmed by non-contrast brain CT, additional tests are performed to evaluate the cause.

CT angiography (CTA) and MR angiography (MRA) are performed to exclude secondary causes such as AVM, aneurysm, and dural AVF. In young ICH patients under 45, normotensive ICH, and lobar ICH, the likelihood of a secondary cause is high, so vascular imaging is strongly recommended. MRI (T2*, SWI, FLAIR, DWI) is the standard for evaluating CAA-related imaging findings—multiple microbleeds, cortical superficial siderosis, white matter changes. The Boston criteria v2.0 are used to classify the likelihood of a CAA diagnosis.

The ICH score is a clinical tool predicting 30-day mortality, summing five items—GCS (2–4: 2 points, 5–12: 1 point), age (≥80 years: 1 point), hematoma volume (≥30 mL: 1 point), accompanying IVH (intraventricular hemorrhage) (1 point), cerebellar or brainstem location (1 point)—for a total of 0–6 points. The higher the score, the more steeply mortality rises. DSA is performed when a secondary cause is suspected on CTA but unclear, and especially for endovascular treatment in cases of active or retrograde bleeding.


10. Treatment

Acute intensive care of intracerebral hemorrhage (V268) aims to prevent hematoma expansion, control intracranial pressure, provide neuroprotection, and prevent secondary complications.

Blood pressure control: The INTERACT2 and ATACH-2 studies evaluated whether rapid lowering to SBP 140 mmHg in ICH patients with SBP 150–220 mmHg is safe and may benefit functional recovery. The current AHA/ASA 2022 guideline recommends an SBP target of 140 mmHg as standard. Intravenous nicardipine, labetalol, clevidipine, and others are used. Coagulation reversal: In warfarin-related ICH, immediate INR reversal with vitamin K and four-factor prothrombin complex concentrate (4F-PCC) is required. In DOAC-related ICH, andexanet alfa (reversal of factor Xa inhibitors) was shown to reduce hematoma expansion in the ANNEXA-I study and has been included in recent guidelines. Idarucizumab is used to reverse dabigatran (a factor IIa inhibitor). Surgical treatment: Cerebellar hemorrhage (diameter > 3 cm or with brainstem compression or hydrocephalus) is a clear indication for surgical evacuation. Hydrocephalus accompanying intraventricular hemorrhage is treated with EVD (external ventricular drainage). In the ENRICH study (NEJM 2023), minimally invasive trans-sulcal parafascicular surgery (MIPS) for supratentorial ICH of 30–80 mL significantly improved mRS at 180 days compared with medical management alone (mRS 0–2 achieved in 27.1% vs. 8.5%).

Intensive care: Includes ICP monitoring (osmotic therapy when ICP > 20–22 mmHg), fever prevention (below 37.5°C), glycemic control (140–180 mg/dL), nutritional support (started within 24–48 hours), deep vein thrombosis prophylaxis (intermittent pneumatic compression), and seizure monitoring. Administration of nimodipine or prophylactic antiseizure medication is optional, and there is currently no routine recommendation.


11. Prognosis

Spontaneous intracerebral hemorrhage is the type with the worst prognosis among all strokes. The 30-day mortality is about 35–50%, and the 1-year mortality reaches about 50–60%. Only about 20–30% of survivors achieve functional independence (mRS 0–2) at 1 year.

Prognostic determinants: ICH score, initial GCS, hematoma volume (> 30 mL poor), accompanying intraventricular hemorrhage (poor), hemorrhage location (brainstem and cerebellum poor), advanced age, unstable vital signs, and anticoagulant use are associated with poor prognosis. In patients who develop hematoma expansion, the likelihood of functional recovery is markedly lower. Early neurological deterioration within 48–72 hours of admission directly affects prognosis in about 30% of patients in whom it occurs. The recurrence rate in ICH survivors is about 2–4% per year, and higher in CAA-related ICH (about 4–10%/year). Long-term complications such as cognitive impairment, epilepsy, depression, and anxiety greatly reduce quality of life.


12. Prevention

Prevention of intracerebral hemorrhage centers on controlling modifiable risk factors.

Hypertension control is the most important and effective means of primary prevention. Keeping blood pressure below 130/80 mmHg is estimated to reduce ICH risk by about 50%. In Korea, improving hypertension prevalence and control rates is a key public health task for reducing the ICH burden. Smoking cessation reduces ICH risk and is especially important in CAA-related ICH because smoking worsens vascular damage. Alcohol restriction is important because excessive drinking increases ICH risk through elevated blood pressure, coagulation abnormalities, and impaired platelet function. Careful use of anticoagulants: In patients who require anticoagulants, maintaining an appropriate dose, attention to interacting drugs, INR monitoring (warfarin), and appropriate DOAC dosing are important. The timing of resuming anticoagulants after ICH is decided by individual risk–benefit assessment, and resumption is generally considered after at least 4–6 weeks. Fall prevention (preventing traumatic intracranial hemorrhage from falls in patients taking anticoagulants) and careful reassessment of statin use (considering bleeding risk in CAA patients) are also important elements of secondary prevention.


13. References

  1. Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke. 2022;53(7):e282-e361. DOI: 10.1161/STR.0000000000000407. PMID: 35579034.

  2. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage (INTERACT2). N Engl J Med. 2013;368(25):2355-2365. DOI: 10.1056/NEJMoa1214609. PMID: 23713578.

  3. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage (ATACH-2). N Engl J Med. 2016;375(11):1033-1043. DOI: 10.1056/NEJMoa1603460. PMID: 27276234.

  4. Hanley DF, Thompson RE, Rosenblum M, et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019;393(10175):1021-1032. DOI: 10.1016/S0140-6736(19)30195-3. PMID: 30739747.

  5. Hemphill JC 3rd, Bonovich DC, Besmertis L, et al. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;32(4):891-897. DOI: 10.1161/01.str.32.4.891. PMID: 11283388.

  6. Connolly SJ, Sharma M, Cohen AT, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors (ANNEXA-I). N Engl J Med. 2023;388(5):418-428. DOI: 10.1056/NEJMoa2210915. PMID: 36342173.

  7. Leasure AC, Kuohn LR, Vanent KN, et al. Association of serum IL-6 with perihematomal edema expansion after intracerebral hemorrhage. Neurology. 2021;96(7):e932-e939. DOI: 10.1212/WNL.0000000000011283. PMID: 33441463.

  8. Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013. Neuroepidemiology. 2015;45(3):161-176. DOI: 10.1159/000441085. PMID: 26505981.

  9. Dastur CK, Yu W. Current management of spontaneous intracerebral haemorrhage. Stroke Vasc Neurol. 2017;2(1):21-29. DOI: 10.1136/svn-2016-000047. PMID: 28959479.

  10. Woo D, Falcone GJ, Devan WJ, et al. Meta-analysis of genome-wide association studies identifies 1q22 as a susceptibility locus for intracerebral hemorrhage. Am J Hum Genet. 2014;94(4):511-521. DOI: 10.1016/j.ajhg.2014.02.012. PMID: 24656865.